Geron Corporation

GERN · Nasdaq · United States

Share price · GERN

$0.99-0.54 (-35.24%) 3M

close as of 2026-11-18 · 24h delayed · vol 35.0M (2.4x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when GERN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 4 Nov 2026+16.1%
  2. 28 Oct 2026-15.8%
  3. 11 Aug 2026+10.1%
  4. 7 Aug 2026-5.7%
  5. 5 Aug 2026+21.6%
  6. 30 Jul 2026-4.3%
  7. 6 Jul 2026+5.9%
  8. 1 Apr 2026+11.4%
  9. 25 Feb 2026-11.8%
  10. 24 Feb 2026+10.2%

Share of unusual movement by asset

For each asset, the share of GERN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Imetelstat (Rytelo)
events and moves
6shown from 8 days
Assets with fewer than 8 event days, together—7%
Other company news (earnings, financing, releases naming no asset)—39%
Sessions with no dated event—54%

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Imetelstat(Rytelo)
Approved
TelomeraseRNA / oligonucleotide
Myelodysplastic Syndromes

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
June 2028 (1)
Imetelstat · RyteloPhase 3Myelofibrosis
Est. primary completion 2028-06-30 · NCT04576156 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$60M$13M$69M+ $217M short-term inv.—$10M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$57M$22M$63M+ $238M short-term inv.$17M-$16M operating cash flowreport ↗
2026-Q1$52M$15M$69M+ $244M short-term inv.$3.6M-$63M operating cash flowreport ↗
2025-Q3$47M$21M$78M+ $302M short-term inv.$18M-$14M operating cash flowreport ↗
2025-Q2$49M$22M$78M+ $310M short-term inv.$16M-$27M operating cash flowreport ↗
2025-Q1$40M$15M$84M+ $313M short-term inv.$20M-$48M operating cash flowreport ↗
2024-Q3$28M$20M$60M+ $279M short-term inv.$26M-$59M operating cash flowreport ↗
2024-Q2$0.9M$31M$117M+ $246M short-term inv.$67M-$53M operating cash flowreport ↗
2024-Q1$0.3M$29M$190M+ $253M short-term inv.$55M-$62M operating cash flowreport ↗
2023-Q3$0.2M$29M$31M+ $283M short-term inv.$45M-$51M operating cash flowreport ↗
2023-Q2<$0.1M$35M$57M+ $314M short-term inv.$49M-$30M operating cash flowreport ↗
2023-Q1<$0.1M$27M$113M+ $268M short-term inv.$38M-$46M operating cash flowreport ↗
2022-Q3$0.3M$25M$61M+ $134M short-term inv.$41M-$30M operating cash flowreport ↗
2022-Q2$0.1M$21M$76M+ $143M short-term inv.$28M-$29M operating cash flowreport ↗
2022-Q1$0.1M$22M$31M+ $135M short-term inv.$30M-$34M operating cash flowreport ↗
2021-Q3$0.1M$19M$29M+ $147M short-term inv.$27M-$23M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$71M$78M+ $280M short-term inv.$21M-$111M operating cash flowreport ↗

Geron reported full-year 2025 product revenue net of $183.6M and total revenues of $183.9M, compared with $76.5M and $77.0M in 2024. R&D expenses were $73.7M (R&D spend was listed at $71.43M, down 31.1% YoY). Year-end cash, cash equivalents, restricted cash and marketable securities were approximately $401.1M, and the full-year net loss was $85.8M with quarterly net burn of $83.5M.

For 2026, Geron guided RYTELO net product revenue to $220M-$240M and total operating expenses to $230M-$240M. The company highlighted a 9% sequential Q4 increase in RYTELO demand, about 1,300 ordering accounts, new medical publications, and ASH 2025 data, along with a December 2025 workforce reduction of approximately one-third and $17.0M in restructuring charges. Pipeline catalysts include the IMpactMF interim analysis in relapsed/refractory myelofibrosis and initial real-world evidence data in LR-MDS, both expected in the second half of 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$104M$79M+ $328M short-term inv.$44M-$219M operating cash flowreport ↗
2023-FY$0.2M$125M$70M+ $264M short-term inv.$46M-$168M operating cash flowreport ↗
2022-FY$0.6M$96M$57M+ $116M short-term inv.$35M-$127M operating cash flowreport ↗
2021-FY$1.4M$86M$35M+ $149M short-term inv.$29M-$96M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 2 purchases ($62K), 1 sale ($19K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-16Williams Timothy · EVP and Chief Legal OfficerOpen-market purchase12,000$0.94$11KForm 4
2026-11-13Semerjian Harout · director, President & CEOOpen-market purchase53,500$0.95$51KForm 4
2026-09-30Spiegel Robert J. · directorAward / grant6,351$1.23$8KForm 4
2026-06-30Spiegel Robert J. · directorAward / grant6,103$1.28$8KForm 4
2026-05-20Bir Dawn Carter · directorAward / grant (derivative)220,000——Form 4
2026-05-20McDonald John F · directorAward / grant (derivative)220,000——Form 4
2026-05-20Molineaux Susan · directorAward / grant (derivative)220,000——Form 4
2026-05-20O'Farrell Elizabeth G. · directorAward / grant (derivative)220,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 255 reporting institutions held 497.2M shares ($737.1M, 77.2% of shares outstanding).

#InstitutionSharesValue
1RA CAPITAL MANAGEMENT, L.P.63,771,366$95.0M
2BlackRock, Inc.47,319,779$70.5M
3Soleus Capital Management, L.P.41,508,659$61.8M
4Deep Track Capital, LP31,720,278$47.3M
5STATE STREET CORP30,497,183$45.4M
6VANGUARD CAPITAL MANAGEMENT LLC26,669,029$39.7M
7CITADEL ADVISORS LLC21,576,569$32.1M
8Point72 Asset Management, L.P.20,457,134$30.5M
9Clearbridge Investments, LLC19,620,320$29.2M
10Eversept Partners, LP18,834,883$28.1M
11GEODE CAPITAL MANAGEMENT, LLC13,670,785$20.4M
12MORGAN STANLEY12,665,119$18.9M
13Nantahala Capital Management, LLC11,225,000$16.7M
14GOLDMAN SACHS GROUP INC11,176,591$16.7M
15Vivo Capital, LLC8,671,797$12.9M